🇺🇸 FDA
Patent

US 9803202

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

granted A61PA61P9/00A61P9/04

Quick answer

US patent 9803202 (Oligonucleotide-based inhibitors comprising locked nucleic acid motif) held by MIRAGEN THERAPEUTICS, INC. expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MIRAGEN THERAPEUTICS, INC.
Grant date
Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P9/00, A61P9/04, A61P9/10